Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Thrombolytic agents.

Désiré Collen¹, H Roger Lijnen

¹Center for Molecular and Vascular Biology, KU Leuven, Herestraat 49, B-3000 Leuven, Belgium. desire.collen@med.kuleuven.ac.be

Thrombosis and Haemostasis

|April 21, 2005

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Obituary Professor Osamu Matsuo.

Journal of thrombosis and haemostasis : JTH·2026

Same author

Recombinant human placental growth factor-2 in post-infarction left ventricular dysfunction: a randomized, placebo-controlled, preclinical study.

Basic research in cardiology·2024

Same author

Does butein affect adipogenesis?

Adipocyte·2019

Same author

ADAMTS5 deficiency in mice does not affect cardiac function.

Cell biology international·2019

Same author

Advanced-age C57BL/6JRj mice do not develop obesity upon western-type diet exposure.

Adipocyte·2019

Same author

Deficiency of Bmal1 disrupts the diurnal rhythm of haemostasis.

Experimental gerontology·2019

Same journal

Discontinuation of Oral Anticoagulation After Successful Catheter Ablation for Atrial Fibrillation: Meta-analysis of Randomized Clinical Trials.

Thrombosis and haemostasis·2026

Same journal

Novel/Recurrent Variants in Pakistani Glanzmann Thrombasthenia and Glanzmann-like bleeding diathesis: Insights from NGS Analysis.

Thrombosis and haemostasis·2026

Same journal

Anti-TFPI Single-Domain Antibodies: Novel Rebalancing Therapies for Hemophilia and Other Rare Bleeding Disorders.

Thrombosis and haemostasis·2026

Same journal

The Interaction of Fibrin with Endothelial Cell Receptor N-Cadherin Promotes Fibrin-Dependent Angiogenesis.

Thrombosis and haemostasis·2026

Same journal

Antiphospholipid Antibodies and Atrial Fibrillation: Clinical Implications and the TaPL AF Study Design.

Thrombosis and haemostasis·2026

Same journal

Prasugrel vs. Ticagrelor: Can TUXEDO-2 Settle the Debate?

Thrombosis and haemostasis·2026

See all related articles

Fibrin-specific thrombolytic agents activate plasminogen on fibrin clots, enabling targeted clot degradation. This approach minimizes systemic effects, leading to effective treatment for thromboembolic diseases.

Area of Science:

Biochemistry
Molecular Biology
Pharmacology

Background:

Thrombolytic agents are crucial for treating thromboembolic diseases.
Physiological fibrinolysis involves plasminogen activation and fibrin degradation.
Understanding fibrinolysis mechanisms led to developing targeted therapies.

Purpose of the Study:

To explain the mechanism of fibrin-specific thrombolysis.
To highlight the advantages of fibrin-specific plasminogen activators.
To review the clinical application of these agents.

Main Methods:

Review of molecular mechanisms of fibrinolysis.
Analysis of fibrin-specific plasminogen activators (t-PA, scu-PA, Sak).
Discussion of clinical investigations and outcomes.

Related Experiment Videos

Main Results:

Fibrin-specific agents preferentially activate fibrin-associated plasminogen.
Generated plasmin is protected from inhibition and efficiently degrades fibrin.
Systemic activation of the fibrinolytic system is avoided.

Conclusions:

Fibrin-specific thrombolysis represents a significant advancement in treating thromboembolic conditions.
Tissue-type plasminogen activator (t-PA) and its variants are established treatments.
Targeted fibrinolysis offers improved efficacy and safety.